FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to resuscitation and intensive care, and can be used in respiratory therapy for new coronavirus infection (NCI) COVID-19 in patients on artificial lung ventilation. The method includes passing through the contour of an artificial respiration unit for 48 hours at a dose of 80 ppm, then reducing the dose to 40 ppm and conducting continuous inhalation until signs of acute respiratory distress syndrome are relieved.
EFFECT: use of the invention makes it possible to improve the treatment’s effectiveness and improve the clinical outcomes in patients with NCI COVID-19, who are on artificial lung ventilation.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF RESPIRATORY THERAPY IN NEW CORONAVIRUS INFECTION COVID-19 IN PATIENTS WITH RESPIRATORY FAILURE, WHO ARE ON SPONTANEOUS BREATHING | 2021 |
|
RU2769489C1 |
| METHOD FOR IMPROVING OXYGENATING PULMONARY FUNCTION IN THE PATIENTS WITH A NEW CORONAVIRAL INFECTION (COVID-19) WITH RESPIRATORY FAILURE WHO ARE ON RESPIRATORY SUPPORT | 2020 |
|
RU2735797C1 |
| METHOD FOR PREDICTING THE RISK OF HOSPITAL MORTALITY IN PATIENTS WITH A NEW CORONAVIRUS INFECTION COVID-19 | 2022 |
|
RU2780522C1 |
| METHOD FOR EARLY DETECTION OF NEUROLOGICAL DISORDERS IN PATIENTS WITH COVID-19 | 2021 |
|
RU2779562C1 |
| METHOD OF TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19 WITH SPONTANEOUS RESPIRATION | 2023 |
|
RU2824264C1 |
| METHOD FOR PREOPERATIVE PREPARATION OF PATIENTS WITH LUNG CANCER AFTER SUFFERING COVID-19 ASSOCIATED PNEUMONIA | 2021 |
|
RU2766291C1 |
| METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF THE HUMAN COMPLEMENT SYSTEM FOR PREDICTING THE SEVERITY OF THE COURSE OF A SYSTEMIC INFLAMMATORY REACTION | 2021 |
|
RU2756764C1 |
| TECHNOLOGY OF REHABILITATION-PREVENTIVE NUTRITIONAL SUPPORT IN CORONAVIRUS INFECTION | 2020 |
|
RU2735723C1 |
| METHOD FOR CORONAVIRUS INFECTION TREATMENT | 2021 |
|
RU2751488C1 |
| METHOD FOR TREATING PATIENTS WITH HIV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES WITH MODERATE AND SEVERE COVID-19 | 2022 |
|
RU2793414C1 |
